4.4 Article

A high-dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio

Journal

CLINICAL AND TRANSLATIONAL ALLERGY
Volume 13, Issue 11, Pages -

Publisher

WILEY
DOI: 10.1002/clt2.12315

Keywords

allergen immunotherapy; allergic rhinoconjunctivitis; birch pollen allergy; conjunctival provocation test

Categories

Ask authors/readers for more resources

This study aimed to evaluate the efficacy of different doses of depigmented, polymerized birch pollen extract in treating patients with birch-pollen-induced allergic rhinitis or rhinoconjunctivitis. The results showed that higher doses had better treatment outcomes, with mild or moderate adverse events.
BackgroundSubcutaneous allergen immunotherapy (SCIT) with depigmented, polymerized (DPP) birch pollen extract has been marketed at doses of up to 1000 DPP units/mL since 2001. We sought to determine the dose-dependent efficacy of a DPP birch pollen extract formulation in patients suffering from birch-pollen-induced allergic rhinitis or rhinoconjunctivitis with or without intermittent asthma.MethodsA titrated conjunctival provocation test (CPT) was applied as a surrogate marker. This Phase II randomized, double-blind, parallel-group, dose-ranging clinical trial was performed at 39 centres in Germany, Lithuania and Poland. After randomization to four dose-level groups (100, 1000, 5000 and 10,000 DPP units/mL) and up-dosing, participants received maintenance SCIT with five monthly subcutaneous injections. The primary endpoint was the proportion of patients in whom a higher concentration of birch pollen (vs. baseline) was needed to elicit a positive CPT.ResultsThree hundred forty-three patients were included (mean (range) age: 42.6 (19-70)). The highest CPT responder rates were seen in the higher dose-level groups. In the intention-to-treat analysis, the difference between the 100 and 10,000 groups was statistically significant (p = 0.0118). Although the proportion of patients with >= 1 treatment-emergent adverse events increased with the dose, almost all these events were mild (65.6%) or moderate (18.5%).ConclusionJudging by the results of a CPT, the efficacy/safety ratio in SCIT appears to be favourable for a high-dose-level preparation of a DPP birch pollen extract.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available